Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| STUDY00015357 | Other Identifier | IRB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Usual Care | Placebo Comparator |
| |
| Chemotherapy Toxicity Tool | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chemotherapy toxicity tool | Other | CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate. The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration. |
| Measure | Description | Time Frame |
|---|---|---|
| Unplanned hospitalization rate | Measured at the patient level as a binary outcome (yes/no) based on date of initial visit with the oncologist. | Within 3 months of the Index Visit with the oncologist |
| Measure | Description | Time Frame |
|---|---|---|
| Healthcare contact days | Measured at the patient level as a continuous outcome (number of days). | Within 3 and 6 months of the Index Visit with the oncologist |
| Chemotherapy use rate | Measured at the patient level as a binary outcome (yes/no) if patient ever received systemic cancer-directed treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | United States |
All data will be housed as subset within the existing Center for Learning Health System Science/Center for Quality Outcomes, Discovery and Evaluation database covered by IRB 597 Protocol: STUDY00014481. Patient level data will not be shared with anyone outside the study team. Aggregated data will be shared with quality officials, hospital administrators, and more broadly disseminated in academic meetings and for publication.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Providers, who were selected based on having at least 20 new patients with metastatic solid tumors in a 6-month period in 2021, will be randomized in a 1:1 ratio, stratified by quartiles of patient volume.
Not provided
Not provided
Not provided
|
|
| Oncology Consultation | Other | Oncologists will consult new patient with a new diagnosis of cancer. |
|
| Within 3 months of the Index Visit with the oncologist |
| Chemotherapy modification rate | Measured at the patient level as a binary outcome (yes/no) if patient had dose, schedule, or number of chemotherapy changed. | Within 3 months of the Index Visit with the oncologist |
| Palliative Care Referral | Measured at the patient level as a binary outcome (yes/no) based on presence of a scheduled palliative care appointment | Within 6 months of the Index Visit with the oncologist |
| Chemotherapy toxicity tool use rate | Measured at the patient level as a binary outcome (yes/no) based on whether the oncologist used the tool for that patient. | Within 3 months of the Index Visit with the oncologist |